Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2026OpenNanoOpen Access

Spanlastics as an efficient delivery system for the enhancement of Nilotinib anticancer efficacy: Design, fabrication, and cytotoxic studies against chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

M‎Mohammed Layth ‎HamzahRMRaffah Khamis MahalIAIshraq Kadhim Abbas

Discussion

Loading...

Member takes

Overview

Randomized trial assesses oral bioavailability and cytotoxicity of NLT-loaded spanlastics in chronic myeloid leukemia, suggesting improved treatment outcomes.

Key Points

  • The aim is to optimize NLT-loaded spanlastics to enhance oral bioavailability and therapeutic efficacy of Nilotinib for chronic myeloid leukemia.
  • Optimized NLT-SPLs using Box-Behnken design
  • Conducted pharmacokinetic studies and in vitro cytotoxicity assays
  • Characterized vesicles for size, stability, and drug release
  • Optimized NLT-SPLs increased oral bioavailability by 2.5-fold compared to NLT suspension
  • Significantly extended Tmax and sustained plasma drug concentrations
  • NLT-SPL showed superior cytotoxicity against HL-60 and HEL cells with improved Caco-2 permeability

Cite This Study

‎Hamzah et al. (2026) studied this question.

synapsesocial.com/papers/6a080b84a487c87a6a40da7bhttps://doi.org/10.1016/j.onano.2026.100307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quality by Design and Characterization of Nimodipine Novel Carriers for the Treatment of Hypertension: Assessment of the Pharmacokinetic Profile2024
  2. 2Development and Optimization of Dipyridamole- and Roflumilast-Loaded Nanoemulsion and Nanoemulgel for Enhanced Skin Permeation: Formulation, Characterization, and In Vitro Assessment2024 · 23 citations
  3. 3Implementing Spanlastics for Improving the Ocular Delivery of Clotrimazole: In vitro Characterization, Ex vivo Permeability, Microbiological Assessment and In vivo Safety Study2021 · 113 citations
  4. 4Risk of <scp>QTc</scp> prolongation among cancer patients treated with tyrosine kinase inhibitors2020 · 75 citations
  5. 5Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring2022 · 293 citations